Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Return on Equity (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 15 years of Return on Equity data on record, last reported at 0.7% in Q3 2025.

  • For Q3 2025, Return on Equity fell 19.0% year-over-year to 0.7%; the TTM value through Sep 2025 reached 0.7%, down 19.0%, while the annual FY2024 figure was 0.93%, 30.0% up from the prior year.
  • Return on Equity reached 0.7% in Q3 2025 per NWBO's latest filing, down from 0.73% in the prior quarter.
  • Across five years, Return on Equity topped out at 1.12% in Q2 2023 and bottomed at 0.13% in Q1 2021.
  • Average Return on Equity over 5 years is 0.63%, with a median of 0.73% recorded in 2025.
  • Peak YoY movement for Return on Equity: tumbled -62bps in 2021, then surged 77bps in 2023.
  • A 5-year view of Return on Equity shows it stood at 0.16% in 2021, then soared by 284bps to 0.62% in 2022, then soared by 45bps to 0.89% in 2023, then fell by -5bps to 0.85% in 2024, then fell by -17bps to 0.7% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.7% in Q3 2025, 0.73% in Q2 2025, and 0.78% in Q1 2025.